In the Claims

Claim 1 (currently amended): A pharmaceutical composition which has a healing action and which comprises:

(1) at least one dextran derivative of the general formula $DMC_aB_bSu_c$ in which:

D represents a dextran chain,

MC represents methylcarboxylate groups,

B represents carboxymethylbenzylamide groups,

Su represents sulfate groups,

a, b and c represent the degree of substitution (ds), expressed with respect to the number of free hydroxyl functions in a glucoside unit of the dextran, with MC, B and Su groups, respectively; with a being ≥ 0.6, b being ≥ 0.1 and c being ~~equal to 0 or~~ between 0.1 and 0.5,

which products exhibit a homogeneity in the distribution of the chain sizes which is illustrated by an elution profile of the symmetrical Gaussian type in high-performance steric exclusion chromatography and a homogeneity in the distribution of the charged chemical groups which is illustrated by an elution profile having a single symmetrical peak in low-pressure ion exchange chromatography,

(2) and also at least one pharmaceutically acceptable excipient, with said dextran derivative being present at a unit dose of between 0.1 and 50 mg.

Claim 2 (canceled)

Claim 3 (currently amended): The pharmaceutical composition as claimed in claim 1 wherein said composition has an action on the healing of the gastric mucosa and is adapted for oral ~~-~~administration.

Claim 4 (previously presented): The pharmaceutical composition as claimed in claim 3, wherein the unit dose of said dextran derivative is between 1.5 and 10 mg.

Claim 5 (previously presented): The pharmaceutical composition as claimed in claim 3, wherein said composition is present in the form of a gel, a gastric dressing, a syrup or a potable solution.

Claim 6 (currently amended): The pharmaceutical composition as claimed in claim 3, wherein said dextran derivative is enclosed in a ~~vector~~gastric juice resistant enclosure.

Claim 7 (canceled)

Claim 8 (currently amended): A pharmaceutical composition as claim in claim 1 wherein said composition has an action on muscle healing and is adapted to administration by local external application or by the parenteral route.

Claim 9 (previously presented): The pharmaceutical composition as claimed in claim 8, wherein the unit dose of said dextran derivative is between 0.5 and 50 mg.

Claim 10 (previously presented): The pharmaceutical composition as claimed in claim 8, wherein said composition is present in the form of a gel, an ointment or an isotonic solution.

Claim 11 (canceled)

Claim 12 (currently amended): A pharmaceutical composition as claimed in claim 1, wherein said composition has an action on ocular healing and is present in the form of eye drops or an ophthalmic ointment.

Claim 13 (previously presented): The pharmaceutical composition as claimed in claim 12, wherein the unit dose of said dextran derivative is between 0.1 and 10 mg.

Claim 14 (canceled)

Claim 15 (currently amended): A pharmaceutical composition which has an action on skin healing, which is adapted to topical administration and which comprises:

(1) at least one dextran derivative of the general formula $DMC_aB_bSu_c$ in which:

D represents a dextran chain,

MC represents methylcarboxylate groups,

B represents carboxymethylbenzylamide groups,

Su represents sulfate groups,

a, b and c represent the degree of substitution (ds), expressed with respect to the number of free hydroxyl functions in a glucoside unit of the dextran, with MC, B and Su groups, respectively; with a being ≥ 0.6, b being ≥ 0.1 and c being ~~equal to 0 or~~ between 0.1 and 0.5,

which products exhibit a homogeneity in the distribution of the chain sizes which is illustrated by an elution profile of the symmetrical Gaussian type in high-performance steric exclusion chromatography and a homogeneity in the distribution of the charged chemical groups which is illustrated by an elution profile having a single symmetrical peak in low-pressure ion exchange chromatography,

(2) and also at least one pharmaceutically acceptable excipient,

with said dextran derivative being present at a concentration of less than 10% by weight/volume.

Claim 16 (canceled)

Claim 17 (currently amended): The pharmaceutical composition as claimed in claim 15 for preparing a medicament which has an action on skin healing and which is intended to be administered topically~~16~~, and wherein said composition is in the form of a paste, an ointment, an aqueous liquid, an oily liquid, an aqueous gel, an oily gel, an aerosol, a foam, a microemulsion, a multiple emulsion, liposomes or nanoparticles.

Claim 18 (currently amended): A pharmaceutical composition which is present in the form of an isotonic solution, has an anticomplementary action and which comprises:

(1) at least one dextran derivative of the general formula $DMC_aB_bSu_c$ in which:

D represents a dextran chain,

MC represents methylcarboxylate groups,

B represents carboxymethylbenzylamide groups,

Su represents sulfate groups,

a, b and c represent the degree of substitution (ds), expressed with respect to the number of free hydroxyl functions in a glucoside unit of the dextran, with MC, B and Su groups, respectively; with a being ≥ 0.3, b being ≥ 0.1 and c being ~~equal to 0 or~~ between 0.1 and 0.4,

which products exhibit a homogeneity in the distribution of the chain sizes which is illustrated by an elution profile of the symmetrical Gaussian type in high-performance steric exclusion chromatography and a homogeneity in the distribution of the charged chemical groups which is illustrated by an elution profile having a single symmetrical peak in low-pressure ion exchange chromatography,

(2) and also at least one pharmaceutically acceptable excipient,

with said dextran derivative being present at a unit dose of between 5 and 30 mg.

Claim 19 (canceled)

Claim 20 (canceled).

Claim 21 (original): A dressing, characterized in that it is soaked with the pharmaceutical composition as claimed in claim 15.

Claim 22-24 (canceled)